Marketing-authorisation holder
Cipla (EU) Limited
1 medicine in 1 country, as authorisation holder.
Loading…
Marketing-authorisation holder
1 medicine in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1 medicine
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| Olanzapine Cipla (previously Olanzapine Neopharma) | Olanzapine | EU (EMA) | Withdrawn | 2007 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| European Union (EMA) | 1 | 0 | 1 | CompaniesAll medicines |
Also in the registers of Sweden, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; https://www.gov.uk/government/publications/marketing-authorisations-granted-in-2026; publication updated 7 October 2026; source PDF periods January–September 2026; original bytes acquired 18 October 2026; PDF page/table/exact-authorisation projections by Prognia under OGL v3.0.
Licence: Open Government Licence v3.0; GOV.UK Crown copyright publication and linked factual MHRA grant registers
Läkemedelsverket, Sweden, Läkemedelsprodukter, source extract 2026-10-20, acquired 2026-10-20T20:45:53.483733+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
Report an error or request removalCorrections from the company itself are welcome.
Keep Cipla (EU) Limited’s medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a callOther companies in the same group.